Oncology News and Research

RSS
CytRx commences PROACT Phase 2 clinical trial of bafetinib for advanced prostate cancer

CytRx commences PROACT Phase 2 clinical trial of bafetinib for advanced prostate cancer

FDA grants IRIS clearance for analysis of synovial fluid with iQ200, iRICELL automated microscopy analyzers

FDA grants IRIS clearance for analysis of synovial fluid with iQ200, iRICELL automated microscopy analyzers

Survey reveals lack of public awareness about radiotherapy's importance in treating cancer

Survey reveals lack of public awareness about radiotherapy's importance in treating cancer

Childhood cancer survivors 5 times more likely to get cancer again: Study

Childhood cancer survivors 5 times more likely to get cancer again: Study

Study suggest PET/CT scanning may offer effective breast cancer detection, spread

Study suggest PET/CT scanning may offer effective breast cancer detection, spread

Genetic predisposition reduces breast, ovarian cancer risk with preventive surgeries: Study

Genetic predisposition reduces breast, ovarian cancer risk with preventive surgeries: Study

MSKCC develops new prediction tool to calculate risk for DCIS recurrence after breast-conserving surgery

MSKCC develops new prediction tool to calculate risk for DCIS recurrence after breast-conserving surgery

Study finds acupuncture can control side effects of cancer treatment

Study finds acupuncture can control side effects of cancer treatment

Researchers develop gLQ Model to determine optimal dose level, treatment schedules for high-dose radiation therapies

Researchers develop gLQ Model to determine optimal dose level, treatment schedules for high-dose radiation therapies

ImmunoCellular Therapeutics updates accomplishments in Letter to Shareholders

ImmunoCellular Therapeutics updates accomplishments in Letter to Shareholders

Tibotec submits MAA for investigational HIV drug TMC278 to European Medicines Agency

Tibotec submits MAA for investigational HIV drug TMC278 to European Medicines Agency

Celldex Therapeutics regains worldwide rights to commercialize rindopepimut therapeutic cancer vaccine

Celldex Therapeutics regains worldwide rights to commercialize rindopepimut therapeutic cancer vaccine

GOG to conduct Phase II trial on primary peritoneal cancer

GOG to conduct Phase II trial on primary peritoneal cancer

Millennium publishes article on MLN4924 pathway mechanism in lymphoma

Millennium publishes article on MLN4924 pathway mechanism in lymphoma

Seattle Genetics achieves milestone on Agensys' initiation of AGS-16M8F ADC phase I trial for cancer

Seattle Genetics achieves milestone on Agensys' initiation of AGS-16M8F ADC phase I trial for cancer

Santhera, Ipsen partner to develop and commercialize fipamezole outside North America and Japan

Santhera, Ipsen partner to develop and commercialize fipamezole outside North America and Japan

BDSI announces positive meeting with FDA, Meda on REMS program for ONSOLIS

BDSI announces positive meeting with FDA, Meda on REMS program for ONSOLIS

Celsion receives SBIR grant to develop heat sensitive liposomal technology for cancer treatment

Celsion receives SBIR grant to develop heat sensitive liposomal technology for cancer treatment

Diabetes drug metformin exhibits potential against tobacco-induced lung tumors

Diabetes drug metformin exhibits potential against tobacco-induced lung tumors

Rexahn Pharmaceuticals publishes research article on RX-8243 anti-tumor activity

Rexahn Pharmaceuticals publishes research article on RX-8243 anti-tumor activity

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.